Skip to content

ASSESSMENT OF THE ANALGESIC EFFICACY AND TOLERABILITY OF THE PERIOPERATIVE ASSOCIATION OF KETAMINE WITH OPIATES AFTER POSTERIOR VERTEBRAL FUSION SURGERY IN CHILDREN WITH IDIOPATHIC SCOLIOSIS

ASSESSMENT OF THE ANALGESIC EFFICACY AND TOLERABILITY OF THE PERIOPERATIVE ASSOCIATION OF KETAMINE WITH OPIATES AFTER POSTERIOR VERTEBRAL FUSION SURGERY IN CHILDREN WITH IDIOPATHIC SCOLIOSIS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-000407-41-ES
Enrollment
Unknown
Registered
2012-01-24
Start date
2011-07-01
Completion date
Unknown
Last updated
2014-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

POSTERIOR VERTEBRAL FUSION SURGERY IN CHILDREN WITH IDIOPATHIC SCOLIOSIS MedDRA version: 14.1 Level: LLT Classification code 10036804 Term: Progressive infantile idiopathic scoliosis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

Interventions

Trade Name: KETOLAR 50 mg/ml solución inyectable Pharmaceutical Form: Solution for injection INN or Proposed INN: KETAMINA HIDROCLORURO CAS Number: 1867-66-9 Other descriptive name: KETAMINE HYDROCHLO

Sponsors

FUNDACIÓ SANT JOAN DE DEU
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a) Patients of both genders diagnosed with idiopathic scoliosis aged between 8 and 18 years old. b) Patients of both genders diagnosed with idiopathic scoliosis and candidates for vertebral fusion corrective surgery with instrumentation. c) Patients with ASA 1 or ASA 2. d) Patients and/or parents/tutors consent to participate in the clinical trial. Are the trial subjects under 18? yes Number of subjects for this age range: 60 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: a)Patients with chronic preoperative pain. b)Patients with addiction to narcotics. c)Patients with a history of allergy, contraindication or intolerance to the drugs used. e)Patients unable to understand the patient-controlled analgesia system. f)Patients with mental disorders. g)Reoperated patients. h)Patients requiring elective postoperative ventilation. d)Pregnant patients.

Design outcomes

Primary

MeasureTime frame
Main Objective: To assess the analgesic efficacy of ketamine in the first 72 hours after surgery, measuring the total intake of morphine chloride.;Secondary Objective: ?To assess the analgesic efficacy of the association of Ketamine and opiates after surgery, with pain assessment. ?To assess the tolerability of the association of ketamine and opiates after surgery, considering the incidence of adverse effects. ?To assess the efficacy of the association of ketamine and opiates after surgery, considering the start of oral tolerance. ?To assess the efficacy of the association of ketamine and opiates after surgery, considering the start of deambulation. ?To study the efficacy of the combination of ketamine and opiates after surgery; by evaluating duration of hospital stay. ?To study the analgesic efficacy of the combination of ketamine and opiates at 72 hours after surgery, by assessing the post-operative hyperalgesic zone. ?To study the analgesic efficacy of the combination of ketamine and opiates by considering the incidence of pain 6 weeks after surgery and of chronic pain at 3 and 6 months after surgery.;Primary end point(s): Total morphine intake during the first 72 hours after the surgical intervention, measured in mg/kg body weight. The total morphine intake is recorded in the PCA infusion pumps.;Timepoint(s) of evaluation of this end point: Intergroup variables of the study will be compared with the following tests: Chi-squared for a comparison of proportions and the Student?s t-test to compare the means and ordinal data. In a contrasting hypothesis, a statistically significant difference will be considered to exist between the means (or correlation between variables) when the significance level is below 0.05.

Secondary

MeasureTime frame
Secondary end point(s): ?Pain assessment by the numerical pain scale in resting state and in movement (coughing) every 4 h after completing post-operative morphine infusion. ?Assessment of the incidence of the following adverse effects every 4 hours until completing the post-operative morphine infusion: nausea, vomiting and pruritus, state of sedation, presence of dysphoria, hallucinations, nightmares, diplopia and respiratory depression requiring naloxone. ? Post-operative period until start of oral tolerance. ? Post-operative period until start of deambulation. ? Post-operative period until hospital discharge (post-operative nights of hospital stay). ? Measurement of the hyperalgesic zone of the peri-incisional inflamed and non-inflamed skin 72 hours post-surgery and the length of the incision, assessing the mechanical pain threshold by the quantitative sensorial test. ?Incidence of pain at 6 weeks and chronic pain at 3 and 6 months post-surgery by the numerical pain scale and the DN4 questionnaire (6 weeks and 6 months).;Timepoint(s) of evaluation of this end point: Intergroup variables of the study will be compared with the following tests: Chi-squared for a comparison of proportions and the Student?s t-test to compare the means and ordinal data. In a contrasting hypothesis, a statistically significant difference will be considered to exist between the means (or correlation between variables) when the significance level is below 0.05.

Countries

Spain

Contacts

Public ContactFUNDACIÓ SANT JOAN DE DEU

FUNDACIÓ SANT JOAN DE DEU

rmorales@fjd.org+34936009751

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026